Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17860105 | 0.91 | KMT2A (0.58) | KMT2AMEN1FAAHCASP2MCL1 | |
| SCHEMBL25590102 | 0.86 | MEN1 (0.67) | KMT2AMEN1FAAHCASP2NAAA | |
| SCHEMBL10173167 | 0.86 | KMT2A (0.58) | KMT2AMEN1FAAHCASP2MCL1 | |
| SCHEMBL20174142 | 0.85 | MEN1 (0.71) | KMT2AMEN1FAAHCASP2NAAA | |
| SCHEMBL95875 | 0.84 | — | — | |
| SCHEMBL15482299 | 0.82 | MEN1 (0.54) | KMT2AMEN1FAAHCASP2NAAA | |
| SCHEMBL26700020 | 0.82 | FAAH (0.47) | KMT2AMEN1FAAHCASP2MCL1 | |
| SCHEMBL11333794 | 0.82 | — | — | |
| SCHEMBL11336046 | 0.82 | — | — | |
| SCHEMBL11333738 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020206137-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-7935131-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080177303-A1 | Shape memory polymers | ROCHESTER, UNIVERSITY OF | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | FOLR1, FOLR2, DHFR | KMT2A 1861/4885MEN1 3080/4885FAAH 2677/4885 |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | PBRM1, BRWD1, BRDT | KMT2A 1344/4885MEN1 2807/4885FAAH 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.